Cardiovascular Gastro/Intestinal Gynecology Neuro Orthopedics Ophthalmology Pulmonary Urology Vascular

Acorn has developed a novel cardiac restraint device to mitigate the effects of Congestive Heart Failure (CHF). The target market is patients in class III and IV congestive heart failure (1.5 Million in the U.S.), representing potentially a $1 Billion market. Spray led the first institutional funding for Acorn. Corazon Technologies, Inc. is developing a catheter and solution-based treatment for cardiovascular disease. Initial applications are arterial decalcification and heart valve decalcification. Direct Flow is a company developing a prosthetic aortic heart valve that can be delivered percutaneously (via a catheter) in a non-surgical procedure. SurvivaLink Corporation develops Automatic External Defibrillators, very simple devices for use by non-medical people in the immediate electrical cardioversion of an individual who has just experienced a Sudden Cardiac Arrest. Acquired by Cardiac Science, Inc. (NASDAQ:DFIB): September 2001 Therus Corporation is a seed stage company formed to exploit clinical applications of High Intensity Focused Ultrasound. The management team is evaluating the best commercial applications, including acoustic hemostasis, arterial sealing and tumor ablation, with the long-term vision of non-invasive, image-guided surgery. Tryton is a start-up project focused on developing a propietary coronary stent for bifurication lesions. This specialized application is projected to be about 10% of the $4 Billion stent market.